Get the Stockscreener App
22.94
0.26%
0.06
After Hours:
22.94
Guardant Health Inc stock is traded at $22.94, with a volume of 1.04M.
It is up +0.26% in the last 24 hours and down -10.32% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$22.88
Open:
$22.78
24h Volume:
1.04M
Relative Volume:
0.48
Market Cap:
$2.81B
Revenue:
$643.81M
Net Income/Loss:
$-490.76M
P/E Ratio:
-5.6502
EPS:
-4.06
Net Cash Flow:
$-299.27M
1W Performance:
-2.34%
1M Performance:
-10.32%
6M Performance:
+11.20%
1Y Performance:
-22.60%
1-Day Range:
$22.58
$23.20
1-Week Range:
$22.05
$23.79
52-Week Range:
$15.81
$37.04
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
(GH) Long Term Investment Analysis - Stock Traders Daily
FDA approves first blood test screening for colon cancer - MSN
Canada Pension Plan Investment Board Invests $303,000 in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Scientech Research LLC Buys New Shares in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
7,652 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Commonwealth Equity Services LLC - Defense World
Why CEO of Bay Area 'liquid biopsy' cancer test maker is stepping down - The Business Journals
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)? - Simply Wall St
Hood River Capital Management LLC Takes Position in Guardant Health, Inc. (NASDAQ:GH) - Defense World
First Light Asset Management LLC Increases Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last? - MSN
Guardant Health’s stock up after FDA approves its blood test for colon-cancer screening - MSN
State of New Jersey Common Pension Fund D Sells 67,151 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
When (GH) Moves Investors should Listen - Stock Traders Daily
Edgestream Partners L.P. Has $2.79 Million Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Tempus AI Says Ex-Workers Took Trade Secrets to Guardant Health - Bloomberg Law
Beck Bode LLC Buys 65,794 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo Finance
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long - BioSpace
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long - Business Wire
Guardant Health (NASDAQ:GH) Trading Down 3.5% - MarketBeat
The battle brewing over blood tests for cancer | Today News - Mint
The Battle Brewing Over Blood Tests for Cancer - The Wall Street Journal
Guardant Health (NASDAQ:GH) Shares Gap Down to $26.79 - MarketBeat
Exact Sciences says data support its colon cancer blood test - MedTech Dive
Exact Sciences presents data to bolster colon cancer test - BioWorld Online
Federated Hermes Inc. Sells 44,800 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Exact Sciences says data support its colon cancer blood test - Yahoo Finance
TD Asset Management Inc Lowers Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types - BioSpace
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types - StockTitan
Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights - GlobeNewswire Inc.
115,854 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Pier Capital LLC - MarketBeat
Guardant Health (NASDAQ:GH) Shares Up 4.4% - MarketBeat
GH Makes Bullish Cross Above Critical Moving Average - Nasdaq
Opinion | Science finds new ways to detect cancer, but politics gets in the way - The Washington Post
Guardant Health Gemelli to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy - HIT Consultant
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy - StockTitan
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy - Business Wire
Candriam S.C.A. Reduces Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Guardant Health Reaches False Claims Act Settlement Over Hiring Physician’s Stepdaughter - Policy & Medicine
(GH) Proactive Strategies - Stock Traders Daily
Bank of New York Mellon Corp Buys 309,157 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Manchestertimes
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations - PR Newswire
Guardant Health, Inc. (NASDAQ:GH) Short Interest Up 34.3% in August - MarketBeat
Guardant Health Rings the Opening Bell - Nasdaq
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Elk Valley Times
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
Shareholders in Guardant Health (NASDAQ:GH) have lost 79%, as stock drops 5.8% this past week - Simply Wall St
Guardant Health (NASDAQ:GH) Shares Gap Down to $29.02 - MarketBeat
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):